The PKM2 activator TEPP-46 suppresses kidney fibrosis via inhibition of the EMT program and aberrant glycolysis associated with suppression of HIF-1α accumulation.

Haijie LiuYuta TakagakiAsako KumagaiKeizo Kanasaki Daisuke Koya

Published in: Journal of diabetes investigation (2020)

PKM2 activation could restore the tubular phenotype via suppression of the EMT program and aberrant glycolysis, providing an alternative target to mitigate fibrosis in diabetic kidneys.

Keyphrases

epithelial mesenchymal transition
quality improvement
type diabetes
signaling pathway
nuclear factor
liver fibrosis
endothelial cells
wound healing
inflammatory response
immune response